Table 3.
Outcome measures during the double-blind phase of the study. (Placebo group and propranolol group are analyzed separately).
| Outcome Measure | Placebo (n = 10) | Propranolol (n = 10) | ||||
|---|---|---|---|---|---|---|
| Baseline | End of DB Phase | p | Baseline | End of DB Phase | p | |
| Primary outcome | ||||||
| ESS | 5.68 ± 1.8 | 5.33 ± 2.1 | 0.133 | 6.50 ± 1.84 | 4.47 ± 1.75 | 0.004 |
| Secondary outcomes | ||||||
| Hb g/dL | 10.7 ± 2.5 | 10.7 ± 2.3 | 0.91 | 10.5 ± 2.6 | 11.4 ± 2.02 | <0.001 |
| Total PC units required * | 3 | 5 | 0.346 | 7 | 3 | <0.001 |
| Total IV iron ** | 16 | 14 | 0.233 | 9 | 4 | 0.15 |
| doses required * | ||||||
| QOL | 34.75 ± 10.9 | 40.6 ± 9.11 | 0.03 | 35.1 ± 6.7 | 41 ± 7.39 | 0.048 |
ESS, epistaxis severity score; DB, double-blind; Hb, hemoglobin; PC, packed cells; IV, intravenous; QOL, quality of life. * In the 2 prior months and ** dose, Ferinject 500 mg.